Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: A meta-analysis

Schizophrenia Research

Volumn 113, Issue 2-3, 2009, Pages 181-188

  Potvin, Stéphane ^a,b   Blanchet, Pierre ^c,d   Stip, Emmanuel ^a  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Extrapyramidal symptoms; Meta analysis; Schizophrenia; Substance use disorders

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE;

AKATHISIA; ALCOHOLISM; CANNABIS ADDICTION; CLINICAL TRIAL; COCAINE DEPENDENCE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; META ANALYSIS; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA;

ANTIDIARRHEALS; BASAL GANGLIA DISEASES; BIAS (EPIDEMIOLOGY); CONFOUNDING FACTORS (EPIDEMIOLOGY); DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HUMANS; MALE; PUBMED; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 68049129529     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.06.010     Document Type: Review

References (81)

1. Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol. Bull. 24 (1988) 781-783
2. Akvardar Y., Tumuklu M., Akdede B.B., Ulas H., Kitis A., and Alptekin K. Substance use among patients with schizophrenia in a university hospital. Bull. Clin. Psychopharmacol. 14 4 (2004) 191-197
3. Bailey L., Maxwell S., and Brandabur M.M. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1027 patients. Psychopharmacol. Bull. 33 1 (1997) 177-181
4. Barnes T.R.E. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989) 672-676
5. Barnes T.R.E., and Trauer T. Reliability and validity of a tardive dyskinesia videotape rating technique. Br. J. Psychiatry 140 (1982) 508-515
6. Borenstein M., and Rothstein H. Comprehensive Meta-Analysis: a Computer Program for Research Synthesis (1999), Biostat, Englewood, New Jersey
7. Chouinard G., Ross-Chouinard A., Annabale L., and Jones B.D. The extrapyramidal symptoms rating scale. Can. J. Neurol. Sci. 7 (1980) 233
8. Coldham E.L., Addington J., and Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr. Scand. 106 4 (2002) 286-290
9. Conley R.R., Kelly D.L., and Gale E.A. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr. Res. 33 1-2 (1998) 95-101
10. Cooper H., and Hedges L.V. The Handbook of Research Synthesis (1994), Russell Sage Foundation, New York, NY
11. Dalack G.W., Healy D.J., and Meador-Woodruff J.H. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am. J. Psychiatry 155 11 (1998) 1490-1501
12. Delay J., Deniker P., and Harl J.M. Traitement des états d'excitation et d'agitation par une méthode médicamenteuse dérivée de l'hibernothérapie. Ann. Med. Psychol. 110 2 (1952) 267-273
13. DerSimonian R., and Laird N.M. Meta-analysis in clinical trials. Control. Clin. Trials 7 3 (1986) 177-188
14. Dhopesh V., Macfadden A., Maany I., and Gamble G. Absence of parkinsonism among patients in long-term neuroleptic therapy who abuse cocaine. Psychiatr. Serv. 48 1 (1987) 95-97
15. Dixon L., Weiden P.J., Haas G., Sweeney J., and Frances A.J. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr. Psychiatry 33 2 (1992) 121-122
16. Drake R.E., Osher F.C., Noordsy D.L., Hurlbut S.C., Teague G.B., and Beaudett M.S. Diagnosis of alcohol use disorders in schizophrenia. Schizophr. Bull. 16 (1990) 57-67
17. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., and Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 57 6 (2005) 594-608
18. Duke P.J., Pantelis C., McPhillips M.A., and Barnes T.R.E. Comorbid non-alcohol substance misuse among people with schizophrenia. Br. J. Psychiatry 179 (2001) 509-513
19. Duke P.J., Pantelis C., and Barnes T.R. South Westminster schizophrenia survey: alcohol use and its relationship to symptoms, dyskinesia and illness onset. Br. J. Psychiatry 164 5 (1994) 630-636
20. Ewing J.A. Detecting alcoholism: the CAGE questionnaire. JAMA 252 (1984) 1905-1907
21. Fowler J.S., Volkow N.D., Wang G.J., Gatley S.J., and Logan L. Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl. Med. Biol. 28 5 (2001) 561-572
22. Fox S.H., Kellett M., Moore A.P., Crossman A.R., and Brotchie J.M. Randomised, double-blind, placebo-controlled trial to assess the potential cannabinoid receptor stimulation in the treatment of dystonia. Mov. Disord. 17 1 (2002) 145-149
23. Gorelick D.A., and Cornish J.L. Chapter 5: The pharmacology of cocaine, amphetamines, and other stimulants. In: Graham A.W., et al. (Ed). Principles of Addiction Medicine. 3rd edition (2003), ASAM 157-190
24. Green A.I., Tohen M.F., Hamer R.M., Strakowski S.M., Lieberman J.A., Glick I., Clark W.S., and HGDH Research Group. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr. Res. 66 2-3 (2004) 125-135
25. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised (1976), US Department of Health and Human Services, Rockville, MD DHEW Publication No. ADM
26. Hess C.W., and Saunders-Pullman R. Movement disorders and alcohol misuse. Addict. Biol. 11 2 (2006) 117-125
27. Hunt G.E., Bergen J., and Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr. Res. 54 3 (2002) 253-264
28. Hyman S.E., and Malenka R.C. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat. Neurosci. 2 10 (2001) 695-703
29. Iqbal N., Lambert T., and Masand P. Akathisia: problem of history or concern of today. CNS Spectr. 9 Suppl 14 (2007) 1-13
30. Jacobsen L.K., Giedd J.N., Gottschalk C., Kosten T.R., and Krystal J.H. Quantitative morphology of the caudate and putamen in patients with cocaine dependence. Am. J. Psychiatry 158 8 (2001) 486-489
31. Kapur S., Remington G., Zipursky R.B., Wilson A.A., and Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 57 10 (1995) L103-L107
32. Kavanagh D.J., McGrath J., Saunders J.B., Dore G., and Clark D. Substance misuse in patients with schizophrenia. Drugs 62 5 (2002) 743-755
33. Khantzian E.J. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. In: Allen D. (Ed). The Cocaine Crisis (1987), New York, Plenum Press 65-74
34. Martinez D., Gil R., Slifstein M., Hwang D.R., Huang Y., Perez A., Kegeles L., Talbot P., Evans S., Krystal J., Laruelle M., and Abi-Dargham A. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol. Psychiatry 58 10 (2005) 779-786
35. Martinez D., Broft A., Foltin R.W., Slifstein M., Hwang D.R., Huang Y., Perez A., Frankle W.G., Cooper T., Kleber H.D., Fischman M.W., and Laruelle M. Cocaine dependence and D2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behaviour. Neuropsychopharmacology 29 6 (2004) 1190-1202
36. Maat A., Fouwels A., and de Haan L. Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. Psychopharmacol. Bull. 41 3 (2008) 5-10
37. Margolese H.C., Malchy L., Negrete J.C., Tempier R., and Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr. Res. 67 2-3 (2004) 157-166
38. Martinez-Martin P., Gil-Nagel A., and Gracia L.M. United Parkinson's disease rating scale: characteristics and structure. The Cooperative Multicentric Group. Mov. Disord. 9 1 (1994) 76-83
39. Mattay V.S., and Casey D.E. Chapter 28: Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. In: Hirsch S.R., and Weinberger D. (Eds). Schizophrenia. 2nd edition (2003), Blackwell Publishing, Malden, Massachusetts 552-572
40. McLellan A.T., Kushner H., Metzberg D., Peters R., Smith I., Grisson G., Pettinati H., and Argeriou M. The fifth edition of the Addiction Severity Index. J. Subst. Abuse Treat. 9 (1992) 199-213
41. Miller D.D., McEvoy J.P., Davis S.M., Caroff S.N., Saltz B.L., Chakos M.H., Swartz M.S., Keefe R.S., Rosenheck R.A., Stroup T.S., and Lieberman J.A. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr. Res. 80 1 (2005) 33-43
42. Mohamed S., Bondi M.W., Kasckow J.W., Golshan S., and Jeste D.V. Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia. Int. J. Geriatr. Psychiatry 21 8 (2006) 711-718
43. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., and Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370 9584 (2007) 319-328
44. Moss D.E., Manderscheid P.Z., Montgomery S.P., Norman A.B., and Sandberg P.R. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci. 44 21 (1989) 1521-1525
45. Mueser K.T., Drake R.E., and Wallach M.A. Dual diagnosis: a review of etiological theories. Addict. Behav. 23 6 (1998) 717-734
46. Müller-Vahl K., Kolbe H., Schneider U., and Emrich H.M. Chapter 18: Movements disorders. In: Grotenhermen F., and Russo E. (Eds). Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutical Potential (2002), The Haworth Press, New York 205-214
47. Negrete J.C. Clinical aspects of substance abuse in persons with schizophrenia. Can. J. Psychiatry 48 1 (2003) 14-21
48. Neiman J., Haapaniemi H.M., and Hillbom M. Neurological complications of drug abuse: pathophysiological mechanisms. Eur. J. Neurol. 7 6 (2000) 595-606
49. Nestler E.J., Hyman S.E., and Malenka R.C. Chapter 8: Catecholamines. Molecular Neuropharmacology: a Foundation for Clinical Neuroscience (2001), The McGraw-Hill Companies Inc, New York 167-190
50. O'Brien C.P. Benzodiazepine use, abuse and dependence. J. Clin. Psychiatry 66 Suppl. 2 (2005) 28-33
51. Olivera A.A., Kiefer M.W., and Manley N.K. Tardive dyskinesia in psychiatric patients with substance use disorders. Am. J. Drug Alcohol Abuse 16 1-2 (1990) 57-66
52. Potvin S., Joyal C.C., Pelletier J., and Stip E. Contradictory cognitive capacities in substance-abusing schizophrenia patients: a meta-analysis. Schizophr. Res. 100 1-3 (2008) 242-251
53. Potvin S., Mancini-Marïe A., Fahim C., Mensour B., Lévesque J., Karama S., Beauregard M., Rompré P.P., and Stip E. Increased striatal grey matter densities in patients with schizophrenia and substance use disorder: a VBM study. Psychiatr. Res. Neuroimag. 154 3 (2007) 275-279
54. Potvin S., Sepehry A.A., and Stip E. A meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. Aust. N. Z. J. Psychiatry 41 10 (2007) 792-799
55. Potvin S., Pampoulova T., Mancini-Marië A., Lipp O., Bouchard R.H., and Stip E. Increased extrapyramidal symptoms in schizophrenia patients with a comorbid substance use disorder. J. Neurol. Neurosurg. Psychiatry 77 6 (2006) 796-798
56. Potvin S., Sepehry A.A., and Stip E. A meta-analysis of negative symptoms in dual diagnosis schizophrenia: a meta-analysis. Psychol. Med. 36 4 (2006) 431-440
57. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., and Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264 19 (1990) 2511-2518
58. Rodriguez de Fonseca F., Del Arco I., Martin-Calderon J.L., Gorriti M.A., and Navarro M. Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol. Dis. 5 6 Pt B (1998) 483-501
59. Rosenberg S.D., Drake R.E., and Wolford G.L. Dartmouth assessment of lifestyle instrument (DALI): a substance use disorder screen for people with severe mental illness. Am. J. Psychiatry 155 2 (1998) 232-238
60. Salyers M.P., and Mueser K.T. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr. Res. 48 1 (2001) 109-123
61. Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., and Grant M. Development of the alcohol use disorders identification test/AUDIT: WHO collaborative project on early detection of persons with harmful alcohol consumption. Addiction 88 (1993) 791-804
62. Scheller-Gilkey G., Moynes K., Cooper I., Kant C., and Miller A.H. Early life stress and PTSD symptoms in patients with comorbid schizophrenia and substance abuse. Schizophr. Res. 69 2-3 (2004) 167-174
63. Scheller-Gilkey G., Woolwine B.J., Cooper I., Gay O., Moynes K.A., and Miller A.H. Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics. Am. J. Drug Alcohol Abuse 29 3 (2003) 553-566
64. Scheller-Gilkey G., Thomas S.M., Woolwine B.J., and Miller A.H. Increased early life stress and depressive symptoms in patients with comorbid substance abuse and schizophrenia. Schizophr. Bull. 28 2 (2002) 223-231
65. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47 1 (2002) 27-38
66. Selzer M.L. The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am. J. Psychiatry 127 (1971) 1653-1658
67. Simpson, G.M., 1985. Neurological Rating Scale, vol. ADM 9-101. DHHS/Public Health Service - Alcohol Drug Abuse and Mental Health Administration NIMH Treatment Strategies in Schizophrenia Study.
68. Simpson G.M., and Angus J.W.S. A rating scale for extrapyramidal side-effects in drug-induced extrapyramidal disorders. Acta Psychiatr. Scand. 212 (1970) 11-19
69. Skinner H.A. The drug abuse screening test. Addict. Behav. 7 (1982) 363-371
70. Soni S.D., and Brownlee M. Alcohol abuse in chronic schizophrenics: implications for management in the community. Acta Psychiatr. Scand. 84 3 (1991) 272-276
71. Sprague R., and Kalachnik J.E. Reliability, validity and a total score cut-off for the Dyskinesia Identification System (DISCUS) with mentally ill and mentally retarded population. Psychopharmacol. Bull. 27 1 (1991) 51-58
72. Stockwell T., Murphy D., and Hodgson R. The Severity of Alcohol Dependence Questionnaire: its use, reliability and validity. Br. J. Addict. 78 (1983) 145-155
73. Sullivan E.V., Deshmukh A., De Rosa E., Rosenbloom M.J., and Pfefferbaum A. Striatal and forebrain nuclei volumes: contribution to motor function and working memory deficits in alcoholism. Biol. Psychiatry 57 7 (2005) 768-776
74. Swofford C.D., Scheller-Gilkey G., Miller A.H., Woolwine B., and Mance R. Double jeopardy: schizophrenia and substance use. Am. J. Drug Alcohol Abuse 26 3 (2000) 343-353
75. Swofford C.D., Ksckow J.W., Scheller-Gilkey G., and Inderbitzin L.B. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr. Res. 20 1-2 (1996) 145-151
76. Tauscher J., Küfferle B., Asenbaum S., Taucher-Wisniewski S., and Kasper S. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology 162 1 (2002) 42-49
77. Van Harten P.N., Van Trier J.C.A.M., Horwitz E.H., Matroos G.E., and Hoek H.W. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J. Clin. Psychiatry 59 3 (1998) 128-130
78. Van Os J., Fahy T., Jones P., Harvey I., Toone B., and Murray R. Tardive dyskinesia: who is at risk?. Acta Psychiatr. Scand. 96 3 (1997) 206-216
79. Wang G.J., Volkow N.D., Franceschi D., Fowler J.S., Thanos P.K., Scherbaum N., Pappas N., Wong C.T., Hitzemann R.J., and Felder C.A. Regional brain metabolism during alcohol intoxication. Alcohol. Clin. Exp. Res. 24 6 (2000) 822-829
80. Zaretsky A., Rector N.A., Seeman M.V., and Fornazzari X. Current cannabis use and tardive dyskinesia. Schizophr. Res. 11 1 (1993) 3-8
81. Ziedonis D.M., Smelson D., Rosenthal R.N., Batki S.L., Green A.I., Henry R.J., Montoya I., Parks J., and Weiss R.D. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J. Psychiatr. Pract. 11 5 (2005) 315-339